Silvercrest Asset Management Group LLC Has $144.91 Million Position in Abbott Laboratories (NYSE:ABT)

Silvercrest Asset Management Group LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 6.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,281,146 shares of the healthcare product maker’s stock after acquiring an additional 72,319 shares during the period. Abbott Laboratories makes up about 1.0% of Silvercrest Asset Management Group LLC’s portfolio, making the stock its 10th largest holding. Silvercrest Asset Management Group LLC owned approximately 0.07% of Abbott Laboratories worth $144,910,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in ABT. Redwood Park Advisors LLC bought a new position in Abbott Laboratories during the 4th quarter worth $25,000. Noble Wealth Management PBC bought a new stake in Abbott Laboratories in the 4th quarter valued at about $26,000. NewSquare Capital LLC lifted its holdings in shares of Abbott Laboratories by 78.4% in the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker’s stock worth $27,000 after purchasing an additional 105 shares in the last quarter. WealthTrak Capital Management LLC acquired a new stake in shares of Abbott Laboratories in the 4th quarter worth about $28,000. Finally, Rialto Wealth Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at approximately $29,000. 75.18% of the stock is owned by institutional investors.

Insider Transactions at Abbott Laboratories

In other news, SVP Eric Shroff sold 562 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total value of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares of the company’s stock, valued at approximately $4,417,294.90. The trade was a 1.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sally E. Blount sold 2,600 shares of Abbott Laboratories stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total transaction of $337,116.00. Following the completion of the transaction, the director now directly owns 34,058 shares in the company, valued at $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 95,278 shares of company stock valued at $12,745,859. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $133.39 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The firm has a fifty day simple moving average of $129.31 and a two-hundred day simple moving average of $123.88. The stock has a market capitalization of $232.08 billion, a P/E ratio of 17.44, a PEG ratio of 2.52 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.38 billion. On average, analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th were paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.77%. The ex-dividend date was Tuesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 30.61%.

Wall Street Analysts Forecast Growth

ABT has been the subject of several analyst reports. Barclays increased their price objective on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research note on Thursday, April 17th. Citigroup lifted their price target on Abbott Laboratories from $135.00 to $160.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Stifel Nicolaus raised their target price on Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, April 17th. Raymond James boosted their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday, April 17th. Finally, Royal Bank of Canada lifted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Thursday, April 17th. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.